GB2472327A — Intranasal granisetron formulation

USPTO Abstract

A unit dosage of a dry powder formulation suitable for intranasal administration comprises granisteron, where when administered as prophylaxis to cancer patients prior to chemotherapy, a median Cmaxof at least 4 ng/ml is observed. Preferably, the formulation comprises (a) about 1% to 40% of granisetron; (b) about 50% to about 90% of a first crystalline cellulose with a mean particle diameter of 30µm or less; (c) about 5% to about 15% of second crystalline cellulose with a mean particle diameter of 100µm or less; and (d) about 0.1% to about 5% of a fluidizing agent. A single use device may be provided, which comprises a nozzle 6 for positioning into a patient's nostril; a reservoir 23 that includes a single unit dose of powdered therapeutic formulation; a valve assembly 5 coupled to the reservoir; and an air source linked to an upstream end of the valve assembly.